comparemela.com
Latest Breaking News On - Checkmate 274 - Page 1 : comparemela.com
Dr Galsky on the Efficacy of Adjuvant Nivolumab in the CheckMate 274 Trial in mUC
Matthew Galsky, MD, discusses how updated findings from the phase 3 CheckMate 274 study confirm the efficacy of adjuvant systemic immunotherapy in metastatic urothelial carcinoma.
Matthew-galsky
Tisch-cancer-institute
Translational-research
Genitourinary-medical-oncology
Bladder-cancer
Mount-sinai
Cancers-symposium
New-england-journal
D
Patients-with-metastatic-urothelial-cancer
Adjuvant-nivolumab
Novel Therapy in Urothelial Carcinoma: An Evolving Treatment Landscape
Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.
Urothelial-carcinomas
Urothelial-carcinoma
Bladder-cancer
Urothelial-cancer
Novel-therapy
Combination-therapy
Checkpoint-inhibitors
Targeted-therapy
Enfortumab-vedotin
Pembrolizumab
Avelumab
Adjuvant Treatment Approaches in Muscle-Invasive Bladder Cancer
Centering discussion on several clinical trials, key opinion leaders reflect on the role of adjuvant therapy in muscle-invasive bladder cancer.
Urothelial-carcinomas
Treatment-approaches
Muscle-invasive-bladder
Bladder-cancer
Urothelial-cancer
Urothelial-carcinoma
Adjuvant-therapy
Adjuvant-treatment
Adjuvant-chemotherapy
Adjuvant-nivolumab
Checkmate-274
vimarsana © 2020. All Rights Reserved.